Effects of long term cholesterol lowering on coronary atherosclerosis in patient risk factor subgroups: the Simvastatin/enalapril Coronary Atherosclerosis Trial (SCAT).

Effects of long term cholesterol lowering on coronary atherosclerosis in patient risk factor subgroups: the Simvastatin/enalapril Coronary Atherosclerosis Trial (SCAT). Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Effects of long term cholesterol lowering on coronary atherosclerosis in patient risk factor subgroups: the Simvastatin/enalapril Coronary Atherosclerosis Trial (SCAT). Abstract Text:

Jeffrey R Burton,Koon K Teo,Christopher E Buller,Sylvain Plante,Diane Catellier,Wayne Tymchak,Dylan Taylor,Vladimir Dzavik,Terrence J Montague, ,

This study examined the effects of long term cholesterol lowering therapy with simvastatin on progression and regression of coronary atherosclerosis, as determined by quantitative angiographic end points, in subgroups of patients with known coronary risk factors. In this randomized, placebo controlled clinical trial, the effect of simvastatin on coronary atherosclerosis was compared with that of placebo in 394 patients who had paired coronary angiograms taken an average of four years apart. The effects of treatment on the following prespecified subgroups were examined: sex, age (less than 65 years versus at least 65 years), smoking status (current or previous/never), history of diabetes mellitus or hypertension, and severity of coronary artery lesions (diameter at least 50% versus less than 50%). There were significantly smaller decreases in the average minimum diameters, between closeout and baseline angiograms, in all simvastatin-treated subgroups, compared with placebo. Trends toward or significantly smaller decreases in the average of the mean diameters, and similar smaller increases in percentage diameter stenosis were also seen in all subgroups. The slowing of angiographically demonstrable coronary atherosclerotic narrowing supports the contention that this treatment effect is causally related to the reduction of coronary events repeatedly seen in large outcome clinical trials of lipid lowering therapy. Also, this treatment effect occurs in the presence or absence of the traditional coronary risk factors.

Effects of long term cholesterol lowering on coronary atherosclerosis in patient risk factor subgroups: the Simvastatin/enalapril Coronary Atherosclerosis Trial (SCAT). Publishing Authors By Initials

JR Burton,KK Teo,CE Buller,S Plante,D Catellier,W Tymchak,D Taylor,V Dzavik,TJ Montague, ,

For similar lipids: glycerides: triglycerides research abstracts see: lipids: glycerides: triglycerides research

PUBMED ID PMID:

MEDLINE DATE:

Effects of long term cholesterol lowering on coronary atherosclerosis in patient risk factor subgroups: the Simvastatin/enalapril Coronary Atherosclerosis Trial (SCAT). Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: The Canadian journal of cardiology

VOLUME: 19

Page Numbers: 487-91

Journal Abbreviation:

ISSN: 1916-7075

DAY: 3

MONTH: Apr

YEAR: 2003

Effects of long term cholesterol lowering on coronary atherosclerosis in patient risk factor subgroups: the Simvastatin/enalapril Coronary Atherosclerosis Trial (SCAT). Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8510280

Effects of long term cholesterol lowering on coronary atherosclerosis in patient risk factor subgroups: the Simvastatin/enalapril Coronary Atherosclerosis Trial (SCAT). Keywords Mesh Terms:

KEYWORDS: Triglycerides

MESH TERMS: blood

Chemical & Substance for Abstract: Effects of long term cholesterol lowering on coronary atherosclerosis in patient risk factor subgroups: the Simvastatin/enalapril Coronary Atherosclerosis Trial (SCAT). Information

Substance Name: Simvastatin

Registry Number: 79902-63-9

Grant and Affiliation Information for Effects of long term cholesterol lowering on coronary atherosclerosis in patient risk factor subgroups: the Simvastatin/enalapril Coronary Atherosclerosis Trial (SCAT).

AFFILIATION: University of Alberta Hospitals and Department of Medicine, University of Alberta, Edmonton. JBurton@cha.ab.ca

Country: Canada

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Can J Cardiol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Effects of long term cholesterol lowering on coronary atherosclerosis in patient risk factor subgroups: the Simvastatin/enalapril Coronary Atherosclerosis Trial SCAT Related Publications

• Cause-specific noncardiac mortality in patients with congestive heart failure--a contemporary Canadian audit. Clinical Quality Improvement Network (CQIN) Investigators.
• Clinical efficacy of emergency bypass surgery for failed coronary angioplasty.
• Contemporary disease management in Quebec.
• Contemporary medical management of left ventricular dysfunction and congestive heart failure.
• Effects of long term cholesterol lowering on coronary atherosclerosis in patient risk factor subgroups: the Simvastatin/enalapril Coronary Atherosclerosis Trial (SCAT).
• Elective irradiation with the electron beam after mastectomy for breast cancer.
• Electromagnetic implantable middle ear hearing device of the ossicular-stimulating type: principles, designs, and experiments.
• Geriatric aspects of rectal diseases.
• Home training for preschool deaf children through correspondence.
• Human ecchordosis physaliphora and chick embryonic notochord. A comparative electron microscopic study.
• In vivo skeletal muscle metabolism during dynamic exercise and recovery: assessment by nuclear magnetic resonance spectroscopy.
• Long term clinical outcomes following isolated mitral valve replacement.
• Long term follow-up after isolated aortic valve replacement.
• Malignant masses in the therapeutically irradiated breast.
• Metabolism of normal skeletal muscle during dynamic exercise to clinical fatigue: in vivo assessment by nuclear magnetic resonance spectroscopy.
• Neural signature of fictive learning signals in a sequential investment task.
• Nonpharmacologic treatment of erectile dysfunction.
• Nonrheumatic atrial fibrillation: a brief overview.
• Optimizing healthcare at the population level: results of the improving cardiovascular outcomes in nova scotia partnership.
• Penile prosthesis implantation for end-stage erectile dysfunction after radical prostatectomy.
• Proceedings: Radiotherapy of breast cancer: guidelines according to features of disease.
• Q-wave infarction: pathophysiology of body surface potential map and ventriculographic patterns in anterior and inferior groups.
• Quantitative relation of electrocardiographic and angiocardiographic measures of risk in patients with coronary atherosclerosis. Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT) Investigators.
• Rationale and design features of a clinical trial examining the effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). SCAT Investigators.
• Recognition memory as a function of encoding strategy and stimulus codability.
• Short-term memory traces for action bias in human reinforcement learning.
• The changing clinical profile of coronary artery bypass graft patients, 1970-89.
• The first wave.
• The treatment and prevention of coronary heart disease in Canada: do older patients receive efficacious therapies? The Clinical Quality Improvement Network (CQIN) Investigators.
• The utilization of antithrombotic prophylaxis for atrial fibrillation in a geriatric rehabilitation hospital.